European drug companies lobby for protections if there are problems with new Covid-19 vaccines
European vaccine makers want EU exemptions that would protect them if there are problems with new Covid-19 vaccines, and low interest rates have helped US homebuilder stocks surge to record highs. Plus, the FT’s James Fontanella-Khan explains why Ant Group chose to list its potentially record setting IPO outside the US.
Covid-19 vaccine makers lobby EU for legal protection
Low rates help propel US homebuilder stocks to record highs
Ant Group reveals $2.6bn profit as it files for blockbuster IPO
See acast.com/privacy for privacy and opt-out information.
A transcript for this podcast is currently unavailable, view our accessibility guide.
Get alerts on FT News Briefing when a new story is published